iBio, Inc. (IBIO) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
600 MADISON AVENUE, SUITE 1601 NEW YORK, NY 10022-1737 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 MRQ | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 7,015 | 14,210 | 7,579 | 28,672 | 96,974 | 55,112 | |||
| Cash and cash equivalent | 7,015 | 14,210 | 4,301 | 22,676 | 77,404 | 55,112 | |||
| Short-term investments | 19,570 | ||||||||
| Other undisclosed cash, cash equivalents, and short-term investments | 3,278 | 5,996 | |||||||
| Restricted cash and investments | 3,025 | ||||||||
| Receivables | 713 | 1,000 | 426 | 75 | |||||
| Inventory, net of allowances, customer advances and progress billings | 3,900 | ||||||||
| Inventory | 3,900 | ||||||||
| Asset, held-for-sale, not part of disposal group | 18,065 | ||||||||
| Other undisclosed current assets | 1,270 | 749 | (2,410) | 11,498 | 7,197 | 6,561 | |||
| Total current assets: | 8,285 | 15,672 | 26,259 | 45,070 | 104,597 | 61,748 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 203 | 339 | 610 | 74 | 26,111 | 27,616 | |||
| Operating lease, right-of-use asset | 2,230 | 2,401 | 2,722 | 5,020 | |||||
| Property, plant and equipment | 3,391 | 3,632 | 4,219 | 36,661 | 8,628 | 3,657 | |||
| Long-term investments and receivables | 1,115 | 1,081 | |||||||
| Accounts and financing receivable, after allowance for credit loss | 1,115 | 1,081 | |||||||
| Intangible assets, net (including goodwill) | 6,108 | 5,368 | 5,388 | 4,851 | 952 | 1,144 | |||
| Intangible assets, net (excluding goodwill) | 6,108 | 5,368 | 5,388 | 4,851 | 952 | 1,144 | |||
| Prepaid expense | 116 | 74 | |||||||
| Restricted cash and investments | 223 | 215 | 253 | 5,996 | |||||
| Other undisclosed noncurrent assets | 26 | 26 | 1,756 | 1,660 | 6,680 | 24 | |||
| Total noncurrent assets: | 13,412 | 13,062 | 14,948 | 54,336 | 42,371 | 32,441 | |||
| TOTAL ASSETS: | 21,697 | 28,734 | 41,207 | 99,406 | 146,968 | 94,189 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 2,449 | 2,386 | 5,883 | 11,094 | 5,255 | 2,864 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | ✕ | 3,066 | ||||
| Accounts payable | 614 | 358 | 1,849 | 4,264 | 2,254 | 1,759 | |||
| Accrued liabilities | 1,835 | 2,028 | 4,034 | 3,764 | 3,001 | 1,105 | |||
| Deferred revenue | 600 | 200 | 100 | 423 | 1,810 | ||||
| Debt | 1,198 | 818 | 13,209 | 22,207 | 967 | 562 | |||
| Disposal group, including discontinued operation | 1,941 | ||||||||
| Other undisclosed current liabilities | 462 | 436 | 549 | (2,965) | |||||
| Total current liabilities: | 4,709 | 3,840 | 21,582 | 30,436 | 6,645 | 5,236 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 643 | 882 | 351 | 5,485 | 31,755 | 32,346 | |||
| Long-term debt, excluding current maturities | 643 | 829 | 339 | ||||||
| Finance lease, liability | 53 | 351 | 30 | 31,755 | 32,007 | ||||
| Liabilities, other than long-term debt | 2,450 | 2,688 | 3,125 | ||||||
| Operating lease, liability | 2,450 | 2,688 | 3,125 | 5,455 | |||||
| Other undisclosed noncurrent liabilities | 768 | (5,455) | |||||||
| Total noncurrent liabilities: | 3,093 | 3,570 | 4,244 | 5,485 | 31,755 | 32,346 | |||
| Total liabilities: | 7,802 | 7,410 | 25,826 | 35,921 | 38,400 | 37,582 | |||
| Equity | |||||||||
| Equity, attributable to parent | 13,895 | 21,324 | 15,381 | 63,485 | 108,585 | 56,618 | |||
| Common stock | 9 | 9 | 20 | 9 | 217 | 140 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (13) | ||||||||
| Additional paid in capital | 336,086 | 335,162 | 304,301 | 287,619 | 282,058 | 206,931 | |||
| Accumulated other comprehensive loss | (213) | (63) | (33) | ||||||
| Accumulated deficit | (322,200) | (313,847) | (288,940) | (223,930) | (173,627) | (150,420) | |||
| Other undisclosed equity, attributable to parent | 13 | ||||||||
| Equity, attributable to noncontrolling interest | (17) | (11) | |||||||
| Total equity: | 13,895 | 21,324 | 15,381 | 63,485 | 108,568 | 56,607 | |||
| TOTAL LIABILITIES AND EQUITY: | 21,697 | 28,734 | 41,207 | 99,406 | 146,968 | 94,189 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 375 | 225 | 2,383 | 2,371 | 1,638 | |||
| Cost of revenue (Cost of Product and Service Sold) | (216) | (1,462) | ||||||
| Gross profit: | 375 | 225 | 2,167 | 909 | 1,638 | |||
| Operating expenses | (15,935) | (16,859) | (29,343) | (51,857) | (32,020) | (15,641) | ||
| Operating loss: | (15,560) | (16,634) | (29,343) | (49,690) | (31,111) | (14,003) | ||
| Nonoperating income (expense) | 1,326 | 1,191 | 32 | (614) | 7,898 | (2,441) | ||
| Investment income, nonoperating | 552 | 363 | 213 | 185 | 152 | 25 | ||
| Interest and debt expense | 582 | 808 | (83) | (1,412) | (2,454) | (2,466) | ||
| Loss from continuing operations before income taxes: | (13,652) | (14,635) | (29,394) | (51,716) | (25,667) | (18,910) | ||
| Income tax benefit | 5,295 | 55 | ||||||
| Other undisclosed income (loss) from continuing operations | (522) | (6,103) | 83 | |||||
| Loss from continuing operations: | (14,174) | (15,443) | (29,311) | (51,716) | (25,612) | (18,910) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (51,716) | (25,612) | (18,910) | |
| Loss from discontinued operations | (5,069) | (9,464) | (35,699) | |||||
| Other undisclosed net income (loss) | (60) | 1,412 | 2,399 | 2,466 | ||||
| Net loss: | (19,303) | (24,907) | (65,010) | (50,304) | (23,213) | (16,444) | ||
| Net income attributable to noncontrolling interest | 1 | 6 | 5 | |||||
| Net loss attributable to parent: | (19,303) | (24,907) | (65,010) | (50,303) | (23,207) | (16,439) | ||
| Other undisclosed net income (loss) available to common stockholders, basic | 35,699 | (88) | (260) | (21,821) | ||||
| Net loss available to common stockholders, diluted: | (19,303) | (24,907) | (29,311) | (50,391) | (23,467) | (38,260) | ||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 TTM | 6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (19,303) | (24,907) | (65,010) | (50,304) | (23,213) | (16,444) | ||
| Other undisclosed comprehensive income (loss) | 213 | (150) | (30) | (2) | ||||
| Comprehensive loss: | (19,303) | (24,907) | (64,797) | (50,454) | (23,243) | (16,446) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 1 | 6 | 5 | |||||
| Comprehensive loss, net of tax, attributable to parent: | (19,303) | (24,907) | (64,797) | (50,453) | (23,237) | (16,441) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.